Palatin Technologies, Inc. (PTN)
Automate Your Wheel Strategy on PTN
With Tiblio's Option Bot, you can configure your own wheel strategy including PTN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PTN
- Rev/Share 0.684
- Book/Share 0.408
- PB 70.006
- Debt/Equity 0.3341
- CurrentRatio 1.0184
- ROIC -9.5192
- MktCap 742725634.0
- FreeCF/Share -16.374
- PFCF -46.6835
- PE -5.7739
- Debt/Assets 0.0154
- DivYield 0
- ROE 1.121
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PTN | Laidlaw | -- | Buy | -- | $60 | Dec. 12, 2025 |
| Initiation | PTN | Alliance Global Partners | -- | Buy | -- | $50 | Dec. 3, 2025 |
News
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Palatin Technologies, Inc. (the “Company”) — ticker symbol PTN — from NYSE American, since the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) due to the low selling price of the Company's common stock. Trading in the.
Read More
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications planned for Q4 2025; clinical data expected H1 2026 Phase 1 SAD/MAD studies to include patients with hypothalamic obesity Ocular asset collaborations expected in Q2 and Q3 2025 CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it expects to close its previously announced pricing of …
Read More
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyses demonstrated statistically significant symptom clearing (resolution) across multiple endpoints in patients treated with PL9643, compared to placebo.
Read More
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J. , March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition.
Read More
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout expected later this month Novel 'next generation' selective MC4R long-acting peptide and an oral small molecule Multiple clinical trials targeted in calendar year 2025 For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesity Phase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarter Teleconference and Webcast to be held on February 13, 2025, at 11:00 AM ET CRANBURY, N.J. , Feb. …
Read More
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
CRANBURY, N.J. , Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets.
Read More
About Palatin Technologies, Inc. (PTN)
- IPO Date 1997-10-15
- Website https://palatin.com
- Industry Biotechnology
- CEO Carl Spana
- Employees 30